posted
Bought in @.065 Friday after reading up on this one Advectus Life Sciences.Through a collaboration agreement with the University of North Carolina – Chapel Hill, Advectus is currently conducting a series of pre-clinical studies to determine the efficacy of Nanocure™ formulation (P80 DOX-NP). Concurrently, the University of Kentucky Research Foundation Center for Pharmaceutical Science and Technology is conducting stability studies and will manufacture Nanocure™ under current Good Manufacturing Practices (cGMP).
The Company believes Nanocure™ can be developed quickly and is a likely candidate for a ‘fast track’ designation by the Food and Drug Administration (FDA). This development could lead to significant growth in shareholder value.
posted
Off to a good start this morning. now @ .08 x.085 on a million shares traded.
Posts: 443 | From: Valemount | Registered: Dec 2003
| IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
